MediciNova, Inc.

What they do

MediciNova is a biopharmaceutical company focused on developing novel therapeutics for serious diseases with unmet medical needs and a commercial focus on the U.S. market. Its development strategy centers on MN-166 (ibudilast) for indications including progressive multiple sclerosis, ALS, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome. A second candidate, MN-001 (tipelukast), targets fibrotic and metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. The company was incorporated in Delaware in September 2000 and has incurred significant net losses since inception.

Revenue drivers

• Mayo Foundation research services agreement — In December 2024, MediciNova entered an agreement with Mayo Foundation for Medical Education and Research to support clinical research services evaluating MN-166 (ibudilast) in ALS; the company performs pharmacovigilance and clinical research support services and recognizes revenue using the cost-to-cost method. The agreement was amended in August 2025 to extend the initial term until August 2026. This is the only named revenue-generating contract in the excerpts.
• No commercial product revenue — The 10-K business section describes only development-stage programs and does not identify any approved product or product sales. Annual revenue was $409,657 in 2025 and no sales figure was reported for 2024 in the earnings release.
• Grant- and investigator-sponsored development — The company states it intends to advance MN-166 through a combination of investigator-sponsored clinical trials, trials funded by government grants or other grants, and trials funded by MediciNova itself; these arrangements may offset development costs but are not described as revenue sources.

Recent performance

For the fiscal year ended December 31, 2025, MediciNova reported net sales of $409,657, an operating loss of $13,283,002, and a net loss attributable to shareholders of $11,997,957. Net loss per share was $0.24, compared with $0.23 for 2024. At December 31, 2025, total assets were $45,603,109, total equity was $41,586,681, and the shareholders' equity ratio was 91.2%. Cash and cash equivalents were $30.8 million and working capital was $27.2 million as of December 31, 2025. In the latest quarter, revenue rose to $458,439 for the period ended June 30, 2026, from $123,319 in the quarter ended September 30, 2025.

Strategy

The company's stated goal is to build a sustainable biopharmaceutical business through development of differentiated products for serious diseases with unmet medical needs in high-value therapeutic areas. Key strategy elements include pursuing MN-166 (ibudilast) across multiple potential indications with support from non-dilutive financings, and advancing MN-001 (tipelukast) for fibrotic and other diseases. MediciNova says it intends to advance MN-166 through investigator-sponsored trials, government- or other grant-funded trials, and company-funded trials. It also plans to pursue strategic alliances with leading pharmaceutical or biotechnology companies to support later clinical development and commercialization. After proof-of-concept Phase 2 trials, management intends to discuss strategic alliances with companies seeking late-stage product candidates.

Risks

• Continued operating losses — MediciNova had a net loss of $12.0 million in 2025 and $11 million in 2024, with an accumulated deficit of $438.7 million at December 31, 2025, and expects substantial net losses for the next several years.
• Financing need — The company states there can be no assurance that adequate financing will be available on acceptable terms, and if unable to obtain additional financing it may have to out-license or sell one or more programs or cease operations.
• Cash sufficiency — As of December 31, 2025, MediciNova had $30.8 million in cash and cash equivalents and $27.2 million in working capital, with operating cash flow negative $9.8 million in 2025 and negative in each year from 2021 through 2025.
• Clinical and regulatory uncertainty — MN-166 (ibudilast) and MN-001 (tipelukast) remain development-stage candidates, and the company's future cash requirements will depend on progress in and costs of future planned clinical trials, which could differ from expectations.

Outlook

Management expects to incur substantial net losses for the next several years as it continues developing existing product candidates, and over the long term if it expands research and development programs or acquires or in-licenses products, technologies or businesses. The company intends to pursue strategic alliances with leading pharmaceutical companies to support clinical development and commercialization of MN-166 (ibudilast) and MN-001 (tipelukast). It also expects to advance MN-166 through a mix of investigator-sponsored, grant-funded, and company-funded trials, and MN-001 through similar means. The company states that if it cannot obtain additional financing, it may have to out-license or sell one or more programs or cease operations.